Current Management of Pediatric Vitiligo

  title={Current Management of Pediatric Vitiligo},
  author={Freya Van Driessche and Nanette B. Silverberg},
  journal={Pediatric Drugs},
AbstractVitiligo is a common inflammatory disorder with worldwide prevalence of 0.4–2 % of the population, with half of cases beginning in childhood. The management of childhood vitiligo should be tailored to avoid negative effects on the overall growth and psychological development of the patient. Therapy of vitiligo in childhood is chosen based on the location of the lesions, lesion age, and extent of lesions in the context of the child’s age and the developmental status of the child. There… 

Clinical efficacy analysis of 110 cases of childhood vitiligo with non-surgical combined therapy.

Treatment lasting longer than 1 year is recommended in children with vitiligo and the best repigmentation effect can be achieved by combination therapy in the rapid progression stage.

A child with vitiligo

There are many therapeutic options for vitiligo, none of which is fully effective, hence appropriate patients education concerning various medical and cosmetic therapies, as well as the psychological aspects of the disease is extremely important.

Therapeutic interventions to lessen the psychosocial effect of vitiligo in children: A review

There is an ongoing need for studies to better understand the modalities described in this article, as well as others, such as skin dyes, bleaching creams, medical tattooing; week‐long camps that cater to children with chronic skin disease; and biofeedback, that might have a role in preventing the psychosocial sequelae of childhood vitiligo.

A prospective study of vitiligo cases in Government Dharmapuri Medical College Hospital

  • R. Akila
  • Medicine
    International Journal of Research in Dermatology
  • 2018
100 cases of vitiligo patients attending Dermatology outpatient Department at Govt Dharmapuri Medical college hospital during the period of January 2017 to June 2017 were included in the study.

Recent Advances in Pathogenesis and Medical Management of Vitiligo

The unravelling of interferon (IFN)-γ/CXCL10 axis in the causation of melanocyte directed attack and the observation of clinical usefulness of tofacitinib, which blocks the same pathway, give new hope in the direction of targeted therapy in vitiligo.

A holistic review on the autoimmune disease vitiligo with emphasis on the causal factors.

Widespread Depigmented and Hypopigmented Patches

Female patients with longer duration of disease and patients with extensive involvement are more likely to develop autoimmune thyroid disease and anti-nuclear antibody positivity is seen more frequently in female patients and in early-onset disease.

Serum Interleukin 19 in Patients with Vitiligo

The aim of the present study is to evaluate the serum level of IL-19 in patients with Vitiligo to assess its role in VitILigo pathogenesis and its relation with studied disease parameters.

Clinical Use and Molecular Action of Corticosteroids in the Pediatric Age

The aim of this review is to discuss the mechanism of action of corticosteroids, and how their genomic effects have both beneficial and adverse consequences, and to focus on the use of cortiosteroids in different pediatric subspecialties and most common diseases.



Vitiligo Therapy in Children: A Case for Considering Excimer Laser Treatment

Overall, the distribution of vitiligo cases seems to be equal between adult men and women, but in the pediatric population, vitILigo presents significantly more often in girls than in boys.

Childhood vitiligo.

Vitiligo Treatment in Childhood: A State of the Art Review

It is found that narrow‐band ultraviolet B (UVB) has better overall repigmentation rates and safety profile than either topical or oral psoralens and ultraviolet A (PUVA) and the option of no treatment with or without corrective camouflage, is an innocuous alternative to any of these treatment modalities.

Narrow‐band UVB for the treatment of generalized vitiligo in children

Narrow‐band UVB is an effective and well‐tolerated treatment option for childhood vitiligo.

Quality of Life Impairment in Children and Adolescents with Vitiligo

An online parental questionnaire‐based study regarding children ages 0 to 17 years with vitiligo found that an affected BSA of more than 25% was associated with self‐consciousness, difficulty with friendships and schoolwork, and teasing and bullying.

Thyroid abnormalities in pediatric patients with vitiligo in New York City.

The results are comparable to the European literature and highlight the need for thyroid screening in children with vitiligo vulgaris of a generalized nonsegmental type.

Celiac disease in childhood: evaluation of 140 patients.

In order to avoid overlooking CD in patients with extra intestinal symptoms and signs, physicians, especially pediatricians, should be informed about new atypical manifestations of CD.

Pediatric vitiligo.

Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases.